Foreword |
|
xix | |
Preface |
|
xx | |
Acknowledgments |
|
xxi | |
Contributors |
|
xxii | |
The COVID-19 Pandemic |
|
xxv | |
|
Chapter 1 Internal Medicine In The 21St Century-Best Practice, Best Outcomes |
|
|
1 | (4) |
|
|
|
|
General versus sub-specialty medicine |
|
|
1 | (1) |
|
The importance of diagnosis |
|
|
2 | (1) |
|
The physician's role in public health |
|
|
2 | (1) |
|
|
2 | (3) |
|
Chapter 2 Evidence-Based Medicine And Critical Appraisal Of The Literature |
|
|
5 | (12) |
|
|
|
|
5 | (1) |
|
|
5 | (3) |
|
|
5 | (1) |
|
Assessing potential biases in different study designs |
|
|
6 | (2) |
|
Critical appraisal of the literature |
|
|
8 | (1) |
|
Interpreting a study's findings |
|
|
9 | (1) |
|
Interpreting statistical analysis |
|
|
10 | (1) |
|
Interpreting test results |
|
|
11 | (2) |
|
|
13 | (1) |
|
|
13 | (1) |
|
|
13 | (1) |
|
Self-assessment questions |
|
|
14 | (3) |
|
Chapter 3 Clinical Pharmacology And Toxicology |
|
|
17 | (30) |
|
|
|
|
1 Principles Of Clinical Pharmacology |
|
|
18 | (1) |
|
|
18 | (1) |
|
|
19 | (5) |
|
|
19 | (1) |
|
|
19 | (1) |
|
|
19 | (2) |
|
|
21 | (1) |
|
|
21 | (1) |
|
|
22 | (1) |
|
|
22 | (1) |
|
|
23 | (1) |
|
|
24 | (2) |
|
Concentration-response relationships |
|
|
24 | (1) |
|
|
24 | (1) |
|
|
25 | (1) |
|
|
26 | (1) |
|
|
26 | (1) |
|
|
26 | (1) |
|
2 Quality Use Of Medicines |
|
|
26 | (1) |
|
|
27 | (1) |
|
|
27 | (1) |
|
Patient profile and drug profile(s) |
|
|
27 | (1) |
|
|
27 | (1) |
|
The prescribing checklist |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
29 | (1) |
|
Types of drug interaction |
|
|
29 | (1) |
|
Therapeutic drug monitoring (TDM) |
|
|
30 | (1) |
|
|
30 | (1) |
|
|
31 | (1) |
|
|
32 | (1) |
|
Epidemiology of poisoning |
|
|
32 | (1) |
|
Sources of poisons information and advice |
|
|
32 | (1) |
|
Clinical assessment of poisoned patients |
|
|
32 | (1) |
|
|
32 | (1) |
|
|
33 | (1) |
|
Principles of management of poisoned patients |
|
|
33 | (1) |
|
Common poisons and their management |
|
|
34 | (4) |
|
Acetaminophen (paracetamol) |
|
|
34 | (2) |
|
Non-steroidal anti-inflammatory drugs (NSAIDs) |
|
|
36 | (1) |
|
Tricyclic antidepressants |
|
|
36 | (1) |
|
|
36 | (1) |
|
Second generation antipsychotics |
|
|
37 | (1) |
|
|
37 | (1) |
|
Insulin and oral hypoglycemics |
|
|
37 | (1) |
|
|
38 | (1) |
|
|
38 | (1) |
|
Cocaine and crack cocaine |
|
|
38 | (1) |
|
Gammahydroxybutyrate (GHB) |
|
|
38 | (1) |
|
Opioids, such as heroin, morphine or fentanyl |
|
|
39 | (1) |
|
|
39 | (1) |
|
Synthetic cathinones, e.g. `vanilla sky', "ivory wave' |
|
|
39 | (1) |
|
Synthetic cannabinoids, e.g. `spice', `K2' |
|
|
39 | (1) |
|
|
39 | (1) |
|
|
39 | (1) |
|
|
39 | (1) |
|
|
40 | (1) |
|
|
40 | (1) |
|
|
40 | (1) |
|
|
40 | (1) |
|
|
40 | (1) |
|
|
41 | (1) |
|
Terrorism, and use of medical countermeasures |
|
|
41 | (3) |
|
|
41 | (1) |
|
|
41 | (3) |
|
Self-assessment questions |
|
|
44 | (3) |
|
|
47 | (16) |
|
|
|
|
47 | (1) |
|
The flow of genetic information |
|
|
48 | (3) |
|
|
48 | (1) |
|
|
49 | (1) |
|
|
50 | (1) |
|
|
51 | (1) |
|
|
52 | (1) |
|
|
52 | (1) |
|
Breast cancer predispostion genes |
|
|
53 | (1) |
|
Breast and ovarian cancer predisposition genes |
|
|
53 | (1) |
|
Calculating the risks of disease |
|
|
53 | (2) |
|
|
53 | (2) |
|
Genetic testing in medicine |
|
|
55 | (2) |
|
|
55 | (1) |
|
Fluorescence in situ hybridization (FISH) |
|
|
55 | (1) |
|
Chromosomal microarray (molecular karyotype) |
|
|
56 | (1) |
|
Genome-wide association studies |
|
|
56 | (1) |
|
Polymerase chain reaction (PCR) |
|
|
56 | (1) |
|
|
56 | (1) |
|
|
57 | (1) |
|
|
57 | (1) |
|
Common chromosomal genetic conditions |
|
|
57 | (1) |
|
|
57 | (1) |
|
|
57 | (1) |
|
|
57 | (1) |
|
|
57 | (1) |
|
Self-assessment questions |
|
|
58 | (5) |
|
Chapter 5 Medical Imaging For Internists |
|
|
63 | (42) |
|
|
|
64 | (1) |
|
Principles of interpretation in chest X-rays |
|
|
64 | (8) |
|
|
64 | (1) |
|
|
64 | (2) |
|
Lines, tubes and implants |
|
|
66 | (1) |
|
|
66 | (1) |
|
Review areas (`hard to see areas') |
|
|
67 | (1) |
|
|
67 | (5) |
|
2 Thoracic Computed Tomography |
|
|
72 | (1) |
|
Techniques of examination |
|
|
72 | (1) |
|
Principles of interpretation in chest CT |
|
|
72 | (5) |
|
|
74 | (1) |
|
|
74 | (1) |
|
|
74 | (1) |
|
|
75 | (1) |
|
|
76 | (1) |
|
|
76 | (1) |
|
|
76 | (1) |
|
3 Abdominal Computed Tomography |
|
|
77 | (1) |
|
Techniques of examination |
|
|
77 | (1) |
|
|
78 | (1) |
|
|
78 | (1) |
|
Arterial phase CT abdomen (CT angiogram, CTA) |
|
|
78 | (1) |
|
|
78 | (1) |
|
|
78 | (1) |
|
|
78 | (1) |
|
Principles of interpretation in abdominal CT |
|
|
78 | (4) |
|
|
78 | (1) |
|
|
78 | (1) |
|
|
79 | (1) |
|
|
79 | (3) |
|
|
82 | (1) |
|
|
82 | (1) |
|
|
82 | (1) |
|
|
82 | (1) |
|
Background--ultrasound principles |
|
|
82 | (1) |
|
Principles of ultrasound interpretation |
|
|
83 | (2) |
|
Lower limb duplex ultrasound |
|
|
85 | (1) |
|
5 Head Computed Tomography |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
87 | (1) |
|
Principles of interpretation in brain CT |
|
|
87 | (6) |
|
|
88 | (1) |
|
|
88 | (1) |
|
|
88 | (2) |
|
|
90 | (3) |
|
|
93 | (1) |
|
|
93 | (1) |
|
|
93 | (1) |
|
6 Head Magnetic Resonance |
|
|
93 | (1) |
|
|
94 | (5) |
|
|
94 | (1) |
|
|
94 | (1) |
|
|
95 | (1) |
|
Diffusion-weighted imaging (DWI) |
|
|
95 | (3) |
|
|
98 | (1) |
|
Gadolinium-enhanced (GAD) |
|
|
98 | (1) |
|
Magnetic resonance angiography/venography (MRA, MRV) |
|
|
99 | (1) |
|
|
99 | (1) |
|
Magnetic resonance gated intracranial cerebrospinal dynamics (MR-GILD, CSF flow study) |
|
|
99 | (1) |
|
Principles of interpretation in brain MR |
|
|
99 | (4) |
|
|
99 | (1) |
|
|
99 | (1) |
|
|
99 | (1) |
|
|
100 | (3) |
|
|
103 | (1) |
|
|
103 | (1) |
|
|
103 | (1) |
|
7 Positron Emission Tomography (PET) |
|
|
103 | (2) |
|
|
105 | (40) |
|
|
|
|
|
|
|
106 | (1) |
|
Clinical presentations of respiratory disease |
|
|
106 | (1) |
|
|
106 | (4) |
|
|
106 | (1) |
|
|
107 | (1) |
|
|
108 | (1) |
|
|
108 | (1) |
|
|
108 | (1) |
|
Solitary pulmonary nodule (coin lesion) |
|
|
109 | (1) |
|
|
109 | (1) |
|
|
109 | (1) |
|
|
109 | (1) |
|
|
110 | (1) |
|
Overview of the respiratory system and pathophysiology |
|
|
110 | (2) |
|
Functional anatomy and physiology |
|
|
110 | (1) |
|
|
111 | (1) |
|
|
111 | (1) |
|
Oxygen-hemoglobin association-dissociation curve |
|
|
112 | (1) |
|
Acid-base disturbances from a pulmonary perspective |
|
|
112 | (1) |
|
|
112 | (1) |
|
|
112 | (1) |
|
Measurement of lung function |
|
|
112 | (2) |
|
|
112 | (2) |
|
Interpretation of lung volumes |
|
|
114 | (1) |
|
Diffusing capacity for carbon monoxide (DLCOtest) |
|
|
114 | (1) |
|
|
114 | (1) |
|
Interpretation of pulmonary function tests |
|
|
114 | (1) |
|
|
114 | (1) |
|
Respiratory tract defenses |
|
|
114 | (2) |
|
|
114 | (1) |
|
|
115 | (1) |
|
|
116 | (1) |
|
|
116 | (1) |
|
|
116 | (1) |
|
|
116 | (1) |
|
|
116 | (11) |
|
|
116 | (2) |
|
Allergic bronchopulmonary aspergillosis (ABPA) |
|
|
118 | (1) |
|
|
118 | (1) |
|
|
119 | (1) |
|
|
119 | (2) |
|
Chronic obstructive pulmonary disease (COPD) |
|
|
121 | (1) |
|
Interstitial lung disease (ILD) |
|
|
122 | (2) |
|
Idiopathic pulmonary fibrosis |
|
|
124 | (1) |
|
Occupational lung disease |
|
|
124 | (2) |
|
|
126 | (1) |
|
Eosinophilic pulmonary disorders |
|
|
127 | (1) |
|
|
127 | (1) |
|
|
127 | (5) |
|
|
127 | (1) |
|
|
128 | (1) |
|
|
128 | (1) |
|
|
129 | (1) |
|
|
130 | (2) |
|
|
132 | (1) |
|
|
132 | (1) |
|
|
132 | (1) |
|
Indications for a chest drain |
|
|
132 | (1) |
|
Pulmonary vascular disease |
|
|
132 | (2) |
|
Pulmonary hypertension (PH) |
|
|
132 | (1) |
|
|
133 | (1) |
|
|
133 | (1) |
|
|
134 | (1) |
|
Complications of lung transplantation |
|
|
134 | (1) |
|
Respiratory sleep medicine |
|
|
135 | (2) |
|
Overview of sleep medicine |
|
|
135 | (1) |
|
|
135 | (1) |
|
Respiratory sleep disorders |
|
|
135 | (2) |
|
|
137 | (1) |
|
|
137 | (1) |
|
|
137 | (1) |
|
Diagnosis and disease management |
|
|
137 | (2) |
|
|
137 | (1) |
|
Acute respiratory distress syndrome (ARDS) |
|
|
137 | (2) |
|
Mechanical ventilation of the lungs |
|
|
139 | (3) |
|
Non-invasive positive-pressure ventilation (NIV) |
|
|
140 | (1) |
|
Invasive positive-pressure ventilation (IPPV) |
|
|
140 | (1) |
|
Extracorporeal membrane oxygenation (ECMO) |
|
|
141 | (1) |
|
Self-assessment questions |
|
|
142 | (3) |
|
|
145 | (66) |
|
|
Clinical evaluation of the patient |
|
|
146 | (6) |
|
Taking the history--possible cardiac symptoms |
|
|
146 | (2) |
|
|
148 | (4) |
|
Investigation of cardiac disease |
|
|
152 | (8) |
|
Electrocardiography (EKG) |
|
|
152 | (1) |
|
Holter (continuous EKG) monitoring |
|
|
152 | (1) |
|
Ambulatory blood pressure monitoring |
|
|
152 | (3) |
|
Radionuclide ventriculography |
|
|
155 | (1) |
|
|
155 | (1) |
|
|
155 | (3) |
|
Radionuclide myocardial perfusion imaging |
|
|
158 | (1) |
|
Coronary angiography and cardiac catheterization |
|
|
158 | (1) |
|
Coronary CT angiography (CTCA, CCTA) and calcium scoring |
|
|
159 | (1) |
|
Magnetic resonance imaging (MRI) |
|
|
160 | (1) |
|
|
160 | (4) |
|
Cholesterol, lipoproteins, apoproteins |
|
|
161 | (1) |
|
Dyslipidemia and cardiovascular disease (CVD) |
|
|
162 | (2) |
|
Lipid-modifying treatments |
|
|
164 | (1) |
|
Coronary artery disease (CAD) |
|
|
164 | (1) |
|
|
164 | (1) |
|
|
164 | (1) |
|
Stable coronary artery disease |
|
|
165 | (4) |
|
|
165 | (2) |
|
Management to improve prognosis |
|
|
167 | (1) |
|
Management of symptoms in the CHD patient |
|
|
168 | (1) |
|
Management of refractory angina |
|
|
169 | (1) |
|
|
169 | (5) |
|
|
169 | (1) |
|
Pathophysiology of acute coronary syndromes |
|
|
170 | (2) |
|
|
172 | (1) |
|
Management of NSTEACS/NSTEMI |
|
|
173 | (1) |
|
Pharmacological therapy in acute coronary syndromes |
|
|
174 | (1) |
|
|
174 | (1) |
|
|
175 | (3) |
|
|
175 | (1) |
|
Mitral regurgitation (MR) |
|
|
176 | (2) |
|
Mitral valve prolapse (MVP) syndrome |
|
|
178 | (1) |
|
|
178 | (3) |
|
|
178 | (2) |
|
Aortic regurgitation (AR) |
|
|
180 | (1) |
|
|
181 | (1) |
|
|
181 | (1) |
|
Tricuspid regurgitation (TR) |
|
|
182 | (1) |
|
|
182 | (1) |
|
Assessing the severity of valvular heart disease and deciding on surgery |
|
|
182 | (1) |
|
|
182 | (5) |
|
Dilated cardiomyopathy (DCM) |
|
|
182 | (3) |
|
Hypertrophic cardiomyopathy (HCM) |
|
|
185 | (1) |
|
Restrictive cardiomyopathy |
|
|
186 | (1) |
|
|
186 | (1) |
|
|
187 | (8) |
|
|
187 | (1) |
|
|
187 | (1) |
|
Supraventricular premature complexes (ectopics) |
|
|
188 | (1) |
|
Supraventricular tachycardia (SVT) |
|
|
188 | (1) |
|
|
189 | (1) |
|
|
190 | (4) |
|
|
194 | (1) |
|
|
195 | (2) |
|
Bundle branch block (BBB) |
|
|
195 | (1) |
|
Fascicular blocks (hemibtocks) |
|
|
196 | (1) |
|
Atrioventricular (AV) blocks |
|
|
196 | (1) |
|
|
197 | (5) |
|
|
197 | (1) |
|
|
197 | (1) |
|
Diagnosis of congestive heart failure |
|
|
197 | (2) |
|
|
199 | (2) |
|
|
201 | (1) |
|
|
202 | (2) |
|
|
202 | (1) |
|
|
203 | (1) |
|
|
203 | (1) |
|
|
204 | (1) |
|
|
204 | (4) |
|
|
204 | (2) |
|
Pericardial effusion and tamponade |
|
|
206 | (1) |
|
Chronic pericardial disease |
|
|
207 | (1) |
|
Self-assessment questions |
|
|
208 | (3) |
|
|
211 | (14) |
|
|
|
Mechanisms of hypertension |
|
|
211 | (1) |
|
Epidemiological evidence for hypertension and its effects |
|
|
212 | (2) |
|
Definitions of hypertension |
|
|
214 | (2) |
|
Clinical presentations and investigations |
|
|
216 | (1) |
|
Target-organ effects of hypertension |
|
|
216 | (2) |
|
|
216 | (1) |
|
|
217 | (1) |
|
|
217 | (1) |
|
Renal changes secondary to hypertension |
|
|
218 | (1) |
|
|
218 | (1) |
|
Treatment and targets for hypertension control |
|
|
218 | (1) |
|
Specific targets linked to comorbid conditions |
|
|
219 | (1) |
|
Treatment for chronic primary hypertension |
|
|
219 | (2) |
|
|
219 | (1) |
|
|
220 | (1) |
|
|
220 | (1) |
|
Higher stages of hypertension |
|
|
220 | (1) |
|
Treatment in an acute setting |
|
|
221 | (2) |
|
Self-assessment questions |
|
|
223 | (2) |
|
|
225 | (36) |
|
|
|
Inherited cystic kidney disease |
|
|
226 | (3) |
|
Autosomal dominant polycystic kidney disease (ADPCKD) |
|
|
226 | (2) |
|
Medullary sponge kidney (MSK) |
|
|
228 | (1) |
|
Medullary cystic disease and autosomal recessive polycystic disease |
|
|
228 | (1) |
|
Acquired kidney cystic disease |
|
|
229 | (3) |
|
|
229 | (1) |
|
Renal stones/kidney stones |
|
|
229 | (3) |
|
Kidney and urinary tract infection |
|
|
232 | (1) |
|
|
232 | (1) |
|
Clinical presentation, investigation and diagnosis |
|
|
232 | (1) |
|
Treatment and targets for urinary tract infection |
|
|
233 | (1) |
|
Inherited renal basement membrane disease |
|
|
233 | (1) |
|
Thin basement membrane disease |
|
|
233 | (1) |
|
|
233 | (1) |
|
|
233 | (9) |
|
|
233 | (1) |
|
Primary glomerular inflammatory disease |
|
|
234 | (6) |
|
Secondary glomerular inflammatory disease |
|
|
240 | (2) |
|
Sclerosing glomerular disease |
|
|
242 | (2) |
|
|
242 | (1) |
|
Focal sclerosing glomerular nephropathy (FSGN) |
|
|
243 | (1) |
|
|
244 | (1) |
|
|
244 | (1) |
|
Treatment of renovascular disease |
|
|
245 | (1) |
|
Thrombotic thrombocytopenic purpura OTP)/ Hemolytic uremic syndrome (HUS) |
|
|
245 | (1) |
|
|
246 | (1) |
|
Mechanisms of renal injury in hypertension |
|
|
246 | (1) |
|
Clinical presentation, investigation and diagnosis |
|
|
246 | (1) |
|
|
246 | (1) |
|
|
247 | (1) |
|
Mechanisms of scleroderma kidney and renal crisis |
|
|
247 | (1) |
|
Clinical presentation, investigation and diagnosis |
|
|
247 | (1) |
|
Treatment and targets for scleroderma |
|
|
247 | (1) |
|
|
247 | (1) |
|
Clinical presentation, investigation and diagnosis |
|
|
247 | (1) |
|
|
248 | (1) |
|
Chronic kidney disease (CKD) |
|
|
248 | (4) |
|
Classification systems and definitions |
|
|
248 | (1) |
|
|
248 | (1) |
|
Clinical presentations of stage 3 CKD |
|
|
249 | (1) |
|
Clinical presentations of stages 4 and 5 CKD |
|
|
249 | (1) |
|
End-stage renal disease (ESRD) and renal replacement therapy |
|
|
249 | (3) |
|
Acute renal failure--acute kidney injury (AKI) |
|
|
252 | (1) |
|
Tubulo-interstitial diseases |
|
|
252 | (1) |
|
Acute interstitial nephritis (AIN) |
|
|
252 | (1) |
|
Chronic tubulo-interstitial disease |
|
|
253 | (1) |
|
|
253 | (3) |
|
|
253 | (1) |
|
|
254 | (1) |
|
|
254 | (1) |
|
|
255 | (1) |
|
Inherited `channelopathies' associated with hypertension or HYPO/hyperkalemia |
|
|
256 | (1) |
|
Hypokalemic alkalosis (with and without hypertension) |
|
|
256 | (1) |
|
|
256 | (1) |
|
The kidneys in pregnancy and pregnancy-related diseases |
|
|
257 | (2) |
|
Normal adaptations to pregnancy |
|
|
257 | (1) |
|
|
257 | (2) |
|
Self-assessment questions |
|
|
259 | (2) |
|
|
261 | (56) |
|
|
|
|
|
|
|
262 | (2) |
|
Hormones, their transport and action |
|
|
262 | (1) |
|
Feedback control of hormone systems |
|
|
262 | (1) |
|
Evaluating function of hormone systems |
|
|
263 | (1) |
|
Pathogenic mechanisms of hormone disorders |
|
|
263 | (1) |
|
Disorders of the pituitary and hypothalamus |
|
|
264 | (5) |
|
|
264 | (1) |
|
|
265 | (1) |
|
|
266 | (1) |
|
Syndromes of hypersecretion |
|
|
267 | (1) |
|
Surgery and radiotherapy for pituitary tumors |
|
|
268 | (1) |
|
Inflammatory and infiltrative disorders |
|
|
268 | (1) |
|
|
269 | (1) |
|
|
269 | (6) |
|
Physiology and assessment of thyroid function |
|
|
269 | (1) |
|
|
269 | (1) |
|
|
270 | (1) |
|
|
270 | (2) |
|
|
272 | (2) |
|
Goiter and thyroid nodules |
|
|
274 | (1) |
|
|
274 | (1) |
|
|
275 | (1) |
|
Disorders of bone and mineral metabolism |
|
|
275 | (7) |
|
|
275 | (1) |
|
|
275 | (3) |
|
|
278 | (1) |
|
|
279 | (1) |
|
|
280 | (1) |
|
|
280 | (1) |
|
|
281 | (1) |
|
|
282 | (7) |
|
Physiology and assessment of adrenal function |
|
|
282 | (1) |
|
|
282 | (2) |
|
Cortisol excess (Cushing's syndrome) |
|
|
284 | (1) |
|
Primary hyperaldosteronism (Conn's syndrome) |
|
|
285 | (1) |
|
|
286 | (1) |
|
Congenital adrenal hyperplasia (CAH) |
|
|
287 | (2) |
|
Incidentally found adrenal masses Cincidentaloma') |
|
|
289 | (1) |
|
|
289 | (3) |
|
|
289 | (1) |
|
Onset of puberty--physiology |
|
|
289 | (1) |
|
Causes of delayed puberty |
|
|
290 | (1) |
|
Common causes of precocious puberty |
|
|
290 | (2) |
|
Male reproductive endocrinology |
|
|
292 | (1) |
|
|
292 | (1) |
|
|
292 | (1) |
|
Causes of erectile dysfunction |
|
|
293 | (1) |
|
|
293 | (1) |
|
Androgen replacement therapy |
|
|
293 | (1) |
|
Female reproductive endocrinology |
|
|
293 | (3) |
|
|
293 | (1) |
|
Clinical and laboratory evaluation |
|
|
294 | (1) |
|
Hirsutism and hyperandrogenism |
|
|
295 | (1) |
|
Polycystic ovary syndrome (PCOS) |
|
|
295 | (1) |
|
|
295 | (1) |
|
Endocrinology of pregnancy |
|
|
296 | (1) |
|
Neuroendocrine tumors (NETs) |
|
|
296 | (2) |
|
|
296 | (1) |
|
|
297 | (1) |
|
|
297 | (1) |
|
|
297 | (1) |
|
|
297 | (1) |
|
Treatment of malignant NETS |
|
|
298 | (1) |
|
Disorders of multiple endocrine systems |
|
|
298 | (1) |
|
Multiple endocrine neoplasia (MEN) |
|
|
298 | (1) |
|
Other multiple endocrine tumor syndromes |
|
|
299 | (1) |
|
Polyglandular autoimmunity (PGA) syndromes |
|
|
299 | (1) |
|
|
299 | (13) |
|
Overview of energy metabolism |
|
|
299 | (1) |
|
Carbohydrate metabolism and diabetes |
|
|
300 | (9) |
|
Disorders of energy excess--overweight and obesity |
|
|
309 | (2) |
|
|
311 | (1) |
|
Self-assessment questions |
|
|
312 | (5) |
|
Chapter 11 Gastroenterology |
|
|
317 | (52) |
|
|
|
|
|
|
|
318 | (3) |
|
|
318 | (1) |
|
|
318 | (2) |
|
Esophagitis due to causes other than acid reflux |
|
|
320 | (1) |
|
|
321 | (4) |
|
Physiology of acid secretion |
|
|
321 | (1) |
|
Dyspepsia and its management |
|
|
322 | (1) |
|
Gastritis and gastropathy |
|
|
323 | (1) |
|
Peptic ulcer disease (PUD) |
|
|
323 | (1) |
|
|
324 | (1) |
|
Post-gastrectomy complications |
|
|
324 | (1) |
|
|
325 | (1) |
|
|
325 | (11) |
|
|
325 | (1) |
|
|
326 | (7) |
|
|
333 | (1) |
|
|
334 | (1) |
|
|
334 | (1) |
|
Small intestinal bacterial overgrowth (SIBO) |
|
|
335 | (1) |
|
Eosinophilic gastroenteritis (EGE) |
|
|
335 | (1) |
|
Chronic idiopathic intestinal pseudoobstruction (CUP) |
|
|
336 | (1) |
|
|
336 | (1) |
|
|
336 | (5) |
|
Clinical clues to malnutrition |
|
|
336 | (1) |
|
Nutritional assessment in end-stage liver disease |
|
|
336 | (4) |
|
Enteral and parenteral nutrition |
|
|
340 | (1) |
|
|
341 | (9) |
|
Irritable bowel syndrome (IBS) |
|
|
341 | (1) |
|
|
341 | (2) |
|
|
343 | (1) |
|
Inflammatory bowel disease (IBD) |
|
|
343 | (7) |
|
|
350 | (1) |
|
|
350 | (4) |
|
Recommendations for screening and surveillance |
|
|
350 | (2) |
|
Fecal occult blood testing (FOBT) |
|
|
352 | (1) |
|
Malignant potential and surveillance |
|
|
352 | (2) |
|
Gastrointestinal bleeding |
|
|
354 | (3) |
|
|
354 | (1) |
|
|
355 | (1) |
|
|
356 | (1) |
|
Management of iron-deficiency anemia |
|
|
357 | (1) |
|
|
357 | (5) |
|
|
357 | (3) |
|
|
360 | (1) |
|
Autoimmune pancreatitis (AIP) |
|
|
361 | (1) |
|
|
362 | (1) |
|
|
362 | (1) |
|
Self-assessment questions |
|
|
363 | (6) |
|
|
369 | (36) |
|
|
|
|
Liver function tests and their abnormalities |
|
|
370 | (1) |
|
|
370 | (1) |
|
Tests of synthetic function |
|
|
370 | (1) |
|
Noninvasive hepatic fibrosis assessment |
|
|
370 | (1) |
|
Approach to the patient with liver disease |
|
|
370 | (2) |
|
Bilirubin metabolism and jaundice |
|
|
372 | (3) |
|
|
375 | (6) |
|
|
375 | (1) |
|
|
376 | (3) |
|
|
379 | (1) |
|
|
380 | (1) |
|
Other viruses causing hepatitis |
|
|
381 | (1) |
|
Noninvasive assessment of liver fibrosis |
|
|
381 | (1) |
|
|
381 | (2) |
|
|
382 | (1) |
|
|
382 | (1) |
|
|
382 | (1) |
|
|
383 | (2) |
|
|
383 | (2) |
|
Hepatorenal syndrome (HRS) |
|
|
385 | (1) |
|
|
386 | (1) |
|
|
386 | (1) |
|
Spontaneous bacterial peritonitis (SBP) |
|
|
386 | (1) |
|
|
386 | (1) |
|
Portal hypertensive bleeding |
|
|
387 | (1) |
|
|
387 | (1) |
|
Portosystemic encephalopathy (PSE) |
|
|
388 | (2) |
|
|
389 | (1) |
|
|
389 | (1) |
|
|
389 | (1) |
|
Portopulmonary hypertension (POPH) |
|
|
390 | (1) |
|
Hepatopulmonary syndrome (HPS) |
|
|
390 | (1) |
|
|
390 | (1) |
|
Acute liver failure (ALF) |
|
|
391 | (1) |
|
|
391 | (1) |
|
|
392 | (2) |
|
Acetaminophen (paracetamol) and acute liver disease |
|
|
392 | (2) |
|
|
394 | (1) |
|
|
394 | (3) |
|
Budd-Chiari syndrome (BCS) |
|
|
394 | (1) |
|
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) |
|
|
395 | (1) |
|
Wilson's disease (hepatolenticular degeneration) |
|
|
396 | (1) |
|
Alpha-1 anti-trypsin deficiency |
|
|
396 | (1) |
|
|
396 | (1) |
|
Autoimmune liver diseases |
|
|
397 | (1) |
|
Autoimmune hepatitis (AIH) |
|
|
397 | (1) |
|
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) |
|
|
397 | (1) |
|
Systemic disease and the liver |
|
|
398 | (1) |
|
Pregnancy and liver disease |
|
|
398 | (1) |
|
Gallbladder and biliary tree |
|
|
398 | (2) |
|
|
399 | (1) |
|
|
400 | (1) |
|
|
400 | (1) |
|
Acute intermittent porphyria (AIP) |
|
|
400 | (1) |
|
Porphyria cutanea tarda (PCT) |
|
|
400 | (1) |
|
Self-assessment questions |
|
|
401 | (4) |
|
|
405 | (52) |
|
|
|
406 | (2) |
|
|
406 | (1) |
|
Components of the hemostatic system |
|
|
406 | (2) |
|
|
408 | (2) |
|
Predisposition to venous thrombosis |
|
|
408 | (1) |
|
Diagnosis of venous thrombosis |
|
|
409 | (1) |
|
Treatment of venous thromboembolism (VTE) |
|
|
410 | (1) |
|
Post-thrombotic syndrome (PTS) |
|
|
410 | (1) |
|
Antiphospholipid syndrome (APS) |
|
|
410 | (1) |
|
|
411 | (1) |
|
Thrombosis at unusual sites |
|
|
411 | (1) |
|
Cerebral vein thrombosis (CVT) |
|
|
411 | (1) |
|
Portal vein thrombosis (PVT) |
|
|
411 | (1) |
|
|
411 | (1) |
|
|
412 | (3) |
|
Von Willebrand disease (vWD) |
|
|
412 | (2) |
|
|
414 | (1) |
|
|
415 | (1) |
|
Bleeding disorders due to deficiencies of other coagulation factors |
|
|
415 | (1) |
|
|
415 | (2) |
|
Idiopathic thrombocytopenic purpura (ITP) |
|
|
415 | (1) |
|
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome |
|
|
416 | (1) |
|
Disseminated intravascular coagulation (DIC) |
|
|
417 | (2) |
|
|
418 | (1) |
|
|
418 | (1) |
|
Coagulopathy in intensive care patients |
|
|
419 | (1) |
|
Myeloproliferative disorders |
|
|
419 | (5) |
|
|
419 | (2) |
|
Essential thrombocythemia (ET) |
|
|
421 | (2) |
|
Primary myelofibrosis (PMF) |
|
|
423 | (1) |
|
|
424 | (8) |
|
Acute myeloid leukemia (AMD |
|
|
424 | (2) |
|
Acute promyelocytic leukemia (APML) |
|
|
426 | (1) |
|
Acute lymphoblastic leukemia (ALL) |
|
|
427 | (1) |
|
Myelodysplastic syndrome (MDS) |
|
|
427 | (1) |
|
Chronic myeloid leukemia (CML) |
|
|
428 | (2) |
|
Chronic lymphocytic leukemia and other B-cell disorders |
|
|
430 | (2) |
|
|
432 | (3) |
|
|
432 | (1) |
|
|
432 | (1) |
|
Diffuse large B-cell lymphoma (DLBCL) |
|
|
432 | (1) |
|
`Cell of origin' classification of DLBCL |
|
|
433 | (1) |
|
`Double-hit' (DH) and `triple-hit' (TH) lymphomas |
|
|
433 | (1) |
|
|
433 | (1) |
|
|
433 | (1) |
|
Mantle cell lymphoma (MCL) |
|
|
434 | (1) |
|
|
434 | (1) |
|
|
435 | (1) |
|
Histological subtypes and cell biology |
|
|
435 | (1) |
|
|
435 | (1) |
|
|
435 | (1) |
|
|
436 | (2) |
|
Monoclonal gammopathy of uncertain significance (MGUS) |
|
|
436 | (1) |
|
|
436 | (1) |
|
|
436 | (1) |
|
Prognostic markers in myeloma |
|
|
437 | (1) |
|
|
437 | (1) |
|
|
437 | (1) |
|
|
438 | (10) |
|
|
438 | (1) |
|
Common laboratory tests used for diagnostic work-up |
|
|
438 | (1) |
|
Approach to iron-deficiency anemia |
|
|
438 | (2) |
|
Management of iron deficiency |
|
|
440 | (1) |
|
Anemia of chronic disease |
|
|
440 | (1) |
|
|
440 | (1) |
|
|
441 | (1) |
|
|
441 | (2) |
|
|
443 | (5) |
|
|
448 | (1) |
|
Non-immune acquired hemolytic anemias (DAT negative) |
|
|
448 | (1) |
|
|
448 | (1) |
|
Self-assessment questions |
|
|
449 | (8) |
|
|
457 | (36) |
|
|
|
|
|
|
459 | (1) |
|
|
459 | (1) |
|
Basic elements of cancer biology |
|
|
459 | (1) |
|
Essential elements of cancer diagnosis and treatment |
|
|
459 | (1) |
|
|
459 | (1) |
|
|
460 | (1) |
|
|
460 | (1) |
|
|
460 | (1) |
|
|
460 | (1) |
|
|
461 | (1) |
|
|
461 | (1) |
|
|
461 | (1) |
|
Prognostic vs predictive factors |
|
|
461 | (1) |
|
|
461 | (1) |
|
|
461 | (1) |
|
|
462 | (1) |
|
|
462 | (1) |
|
|
462 | (1) |
|
|
462 | (1) |
|
Principles of chemotherapy |
|
|
462 | (1) |
|
Attitudes to chemotherapy |
|
|
463 | (1) |
|
Toxicity of cytotoxic chemotherapy |
|
|
463 | (1) |
|
Principles of radiotherapy |
|
|
463 | (1) |
|
|
464 | (1) |
|
|
464 | (1) |
|
|
464 | (1) |
|
|
464 | (1) |
|
Potentially curable following chemotherapy alone |
|
|
464 | (1) |
|
Tumors very sensitive to chemotherapy |
|
|
464 | (1) |
|
Potentially curable following radiotherapy |
|
|
464 | (1) |
|
|
464 | (1) |
|
Molecular targeted therapy |
|
|
464 | (1) |
|
Monoclonal antibodies (the ABs') |
|
|
464 | (1) |
|
Tyrosine kinase inhibitors (the `IBs') |
|
|
465 | (1) |
|
|
465 | (1) |
|
Familial cancers and cancer genetics |
|
|
465 | (1) |
|
|
465 | (2) |
|
|
465 | (1) |
|
|
466 | (1) |
|
|
466 | (1) |
|
|
467 | (1) |
|
Disseminated intravascular coagulation (DIC) |
|
|
467 | (1) |
|
|
467 | (1) |
|
|
467 | (1) |
|
Superior vena cava (SVC) obstruction |
|
|
467 | (1) |
|
Raised intracranial pressure (ICP) |
|
|
467 | (1) |
|
|
467 | (1) |
|
|
468 | (1) |
|
Cancer with unknown primary (CUP) |
|
|
468 | (1) |
|
|
468 | (1) |
|
Potentially treatable subgroups of CUP |
|
|
468 | (1) |
|
Recent research and future directions |
|
|
469 | (1) |
|
|
469 | (2) |
|
|
469 | (1) |
|
|
469 | (1) |
|
Epidemiology and pathology |
|
|
469 | (1) |
|
Non-small-cell lung cancer (NSCLC) |
|
|
469 | (1) |
|
|
469 | (1) |
|
|
469 | (1) |
|
|
469 | (1) |
|
Treatment of stage IV NSCLC |
|
|
470 | (1) |
|
Small cell lung cancer (SCLC) |
|
|
471 | (1) |
|
|
471 | (1) |
|
|
471 | (1) |
|
|
471 | (1) |
|
|
472 | (1) |
|
|
472 | (1) |
|
Tumors of the pelvis, ureter and bladder |
|
|
472 | (1) |
|
|
472 | (1) |
|
|
472 | (1) |
|
|
473 | (1) |
|
Investigation and diagnosis |
|
|
473 | (1) |
|
|
473 | (1) |
|
|
473 | (1) |
|
|
473 | (1) |
|
|
473 | (1) |
|
|
473 | (1) |
|
|
473 | (1) |
|
|
474 | (2) |
|
|
474 | (1) |
|
|
474 | (1) |
|
|
474 | (1) |
|
Prognostic factors in stage I NSGCT |
|
|
475 | (1) |
|
|
475 | (1) |
|
Post-chemotherapy residual masses |
|
|
475 | (1) |
|
|
476 | (1) |
|
High-dose chemotherapy (HDCT) |
|
|
476 | (1) |
|
|
476 | (1) |
|
|
476 | (1) |
|
|
476 | (1) |
|
Human papillomavirus (HPV) infection |
|
|
476 | (1) |
|
|
476 | (1) |
|
Pathology and epidemiology |
|
|
476 | (1) |
|
|
476 | (1) |
|
|
477 | (1) |
|
|
477 | (1) |
|
|
477 | (1) |
|
|
477 | (1) |
|
|
477 | (1) |
|
|
477 | (1) |
|
|
477 | (1) |
|
|
478 | (1) |
|
|
478 | (2) |
|
Pathology and epidemiology |
|
|
478 | (1) |
|
|
478 | (1) |
|
|
479 | (1) |
|
|
480 | (1) |
|
|
480 | (1) |
|
|
480 | (1) |
|
|
480 | (1) |
|
|
480 | (1) |
|
|
480 | (1) |
|
Hepatocellular carcinoma (HCC) |
|
|
481 | (1) |
|
|
481 | (1) |
|
|
481 | (1) |
|
|
481 | (1) |
|
|
481 | (1) |
|
|
482 | (1) |
|
Low-grade glioma (astrocytoma and oligodendroglioma) |
|
|
482 | (1) |
|
Glioblastoma multiforme (GBM) |
|
|
482 | (1) |
|
|
482 | (1) |
|
|
483 | (1) |
|
Pathology and epidemiology |
|
|
483 | (1) |
|
|
483 | (1) |
|
|
483 | (1) |
|
|
483 | (1) |
|
|
483 | (1) |
|
|
483 | (1) |
|
|
484 | (1) |
|
|
484 | (1) |
|
|
484 | (1) |
|
|
484 | (1) |
|
|
484 | (1) |
|
|
485 | (2) |
|
|
485 | (1) |
|
|
485 | (1) |
|
|
485 | (1) |
|
|
485 | (1) |
|
|
485 | (1) |
|
|
485 | (2) |
|
Recent research and future directions |
|
|
487 | (1) |
|
|
487 | (1) |
|
|
487 | (1) |
|
Pathology and epidemiology |
|
|
487 | (1) |
|
|
488 | (1) |
|
|
488 | (1) |
|
|
488 | (1) |
|
|
488 | (1) |
|
Pathology and epidemiology |
|
|
488 | (1) |
|
|
488 | (1) |
|
|
489 | (1) |
|
|
489 | (1) |
|
Self-assessment questions |
|
|
490 | (3) |
|
Chapter 15 Palliative Medicine |
|
|
493 | (14) |
|
|
|
|
|
494 | (2) |
|
|
494 | (1) |
|
|
494 | (1) |
|
|
494 | (1) |
|
Interventions to palliate the problem |
|
|
494 | (2) |
|
|
496 | (1) |
|
|
496 | (1) |
|
|
496 | (1) |
|
|
496 | (1) |
|
|
496 | (1) |
|
|
497 | (1) |
|
|
497 | (1) |
|
|
497 | (1) |
|
|
497 | (1) |
|
Interventions to palliate the problem |
|
|
497 | (1) |
|
|
497 | (3) |
|
|
497 | (1) |
|
|
498 | (1) |
|
|
498 | (1) |
|
Interventions to palliate the problem |
|
|
498 | (2) |
|
|
500 | (1) |
|
|
500 | (1) |
|
|
500 | (1) |
|
Underlying pathophysiological basis |
|
|
500 | (1) |
|
|
501 | (1) |
|
|
501 | (1) |
|
|
501 | (1) |
|
|
501 | (1) |
|
|
501 | (1) |
|
Interventions to palliate the problem |
|
|
502 | (1) |
|
|
502 | (1) |
|
|
502 | (1) |
|
|
502 | (1) |
|
|
502 | (1) |
|
Interventions to palliate the problem |
|
|
502 | (1) |
|
|
502 | (1) |
|
|
502 | (1) |
|
|
502 | (1) |
|
|
503 | (1) |
|
Interventions to palliate the problem |
|
|
503 | (1) |
|
|
503 | (2) |
|
|
503 | (1) |
|
|
503 | (1) |
|
|
503 | (1) |
|
Interventions to palliate the problem |
|
|
504 | (1) |
|
Self-assessment questions |
|
|
505 | (2) |
|
|
507 | (56) |
|
|
|
|
Key concepts in immunobiology |
|
|
508 | (5) |
|
Innate and adaptive immunity |
|
|
508 | (1) |
|
Specificity and diversity |
|
|
509 | (1) |
|
|
510 | (1) |
|
Hypersensitivity, autoimmunity and immunodeficiency |
|
|
511 | (1) |
|
Immunity, inflammation and tissue repair |
|
|
511 | (1) |
|
Understanding immunobiology |
|
|
512 | (1) |
|
Manipulation of the immune system |
|
|
512 | (1) |
|
|
513 | (13) |
|
|
513 | (1) |
|
Allergic rhinitis (AR) and allergic conjunctivitis (AC) |
|
|
514 | (2) |
|
|
516 | (2) |
|
|
518 | (1) |
|
|
519 | (2) |
|
|
521 | (3) |
|
|
524 | (1) |
|
|
525 | (1) |
|
|
526 | (1) |
|
Hypereosinophilic syndrome (HES) |
|
|
526 | (1) |
|
|
527 | (1) |
|
Cutaneous mastocytosis (CM) |
|
|
527 | (1) |
|
Systemic mastocytosis (SM) |
|
|
527 | (1) |
|
Systemic autoimmune disease |
|
|
528 | (12) |
|
Systemic lupus erythematosus (SLE) |
|
|
528 | (4) |
|
|
532 | (3) |
|
|
535 | (1) |
|
|
535 | (2) |
|
Scleroderma and CREST syndrome |
|
|
537 | (1) |
|
Mixed connective tissue disease (MCTD) |
|
|
538 | (1) |
|
Antiphospholipid syndrome (APS) |
|
|
539 | (1) |
|
|
539 | (1) |
|
|
540 | (6) |
|
|
540 | (2) |
|
|
542 | (1) |
|
|
543 | (2) |
|
|
545 | (1) |
|
Variable-vessel vasculitis |
|
|
545 | (1) |
|
Autoinflammatory disorders |
|
|
546 | (1) |
|
Familial Mediterranean fever (FMF) |
|
|
546 | (1) |
|
TNF-receptor-associated periodic syndrome (TRAPS) |
|
|
547 | (1) |
|
|
547 | (3) |
|
|
547 | (3) |
|
Secondary (acquired) immunodeficiency |
|
|
550 | (1) |
|
|
550 | (7) |
|
|
551 | (1) |
|
Risk factors for HIV infection |
|
|
551 | (1) |
|
|
551 | (1) |
|
Clinical features and diagnosis |
|
|
552 | (1) |
|
|
553 | (2) |
|
|
555 | (2) |
|
Self-assessment questions |
|
|
557 | (6) |
|
Chapter 17 Musculoskeletal Medicine |
|
|
563 | (36) |
|
|
|
An approach to a patient with painful joints |
|
|
564 | (2) |
|
|
564 | (1) |
|
|
565 | (1) |
|
|
566 | (1) |
|
Rheumatoid arthritis (RA) |
|
|
566 | (5) |
|
Genetics and environmental contribution to RA |
|
|
566 | (1) |
|
|
567 | (1) |
|
|
567 | (1) |
|
Clinical features and complications |
|
|
567 | (2) |
|
|
569 | (1) |
|
|
569 | (2) |
|
|
571 | (1) |
|
|
571 | (4) |
|
Ankylosing spondylitis (AS) |
|
|
572 | (1) |
|
Psoriatic arthritis (PsA) |
|
|
573 | (1) |
|
|
574 | (1) |
|
IBD-associated spondyloarthropathy |
|
|
575 | (1) |
|
Adult-onset Still's disease (AOSD) |
|
|
575 | (1) |
|
|
575 | (5) |
|
|
575 | (4) |
|
|
579 | (1) |
|
Relapsing polychondritis (RP) |
|
|
580 | (1) |
|
|
580 | (4) |
|
|
581 | (1) |
|
|
581 | (1) |
|
Specific joint involvement |
|
|
581 | (1) |
|
|
582 | (1) |
|
|
582 | (2) |
|
Genetic connective tissue disorders |
|
|
584 | (1) |
|
|
584 | (3) |
|
|
585 | (1) |
|
|
585 | (1) |
|
|
585 | (1) |
|
Frozen shoulder/adhesive capsulitis |
|
|
586 | (1) |
|
Tennis elbow and golfer's elbow |
|
|
587 | (1) |
|
Tennis elbow (lateral epicondylitis) |
|
|
587 | (1) |
|
Golfer's elbow (medial epicondylitis) |
|
|
587 | (1) |
|
|
588 | (1) |
|
|
588 | (2) |
|
Epidemiology and etiology |
|
|
589 | (1) |
|
|
589 | (1) |
|
Prognosis, differential diagnosis and treatment |
|
|
590 | (1) |
|
|
590 | (1) |
|
|
591 | (1) |
|
|
591 | (1) |
|
|
591 | (3) |
|
Specific pathology leading to acute low back pain |
|
|
592 | (1) |
|
|
593 | (1) |
|
|
593 | (1) |
|
|
594 | (1) |
|
|
594 | (1) |
|
|
594 | (1) |
|
|
594 | (1) |
|
Self-assessment questions |
|
|
595 | (4) |
|
|
599 | (58) |
|
|
|
Disorders of consciousness |
|
|
600 | (2) |
|
|
600 | (1) |
|
|
600 | (1) |
|
|
600 | (1) |
|
Assessment of the patient with impaired consciousness |
|
|
601 | (1) |
|
|
602 | (6) |
|
Primary headache syndromes |
|
|
602 | (4) |
|
|
606 | (2) |
|
|
608 | (4) |
|
Acute assessment and management |
|
|
608 | (1) |
|
|
609 | (1) |
|
Neurosurgical intervention |
|
|
610 | (1) |
|
|
611 | (1) |
|
Early secondary prevention |
|
|
611 | (1) |
|
|
612 | (1) |
|
|
612 | (1) |
|
|
612 | (1) |
|
Subarachnoid hemorrhage (SAH) |
|
|
612 | (1) |
|
Natural history and outcome of an aneurysmal SAH |
|
|
612 | (1) |
|
Surgical versus endovascular management of SAH |
|
|
612 | (1) |
|
Transient ischemic attack (TIA) |
|
|
613 | (1) |
|
|
613 | (1) |
|
Differential diagnosis of transient neurological disturbances |
|
|
613 | (1) |
|
|
613 | (1) |
|
|
613 | (1) |
|
|
613 | (1) |
|
Prevention of recurrent events |
|
|
613 | (1) |
|
|
614 | (3) |
|
|
614 | (1) |
|
|
614 | (1) |
|
Diagnostic work-up of the dementia patient |
|
|
615 | (1) |
|
|
615 | (2) |
|
Seizures and the epilepsies |
|
|
617 | (7) |
|
|
617 | (1) |
|
Assessing a patient after a seizure |
|
|
618 | (1) |
|
Investigation of a first seizure |
|
|
619 | (1) |
|
|
619 | (1) |
|
Important epilepsy syndromes |
|
|
619 | (3) |
|
Choice of anticonvulsant therapy |
|
|
622 | (1) |
|
|
622 | (2) |
|
|
624 | (1) |
|
Balance, dizziness and vertigo |
|
|
624 | (5) |
|
Hemodynamic dizziness or `lightheadedness' |
|
|
625 | (1) |
|
|
625 | (2) |
|
|
627 | (1) |
|
Treatment of vertiginous patients |
|
|
628 | (1) |
|
|
629 | (1) |
|
|
629 | (7) |
|
|
629 | (1) |
|
|
630 | (3) |
|
Dementia with Lewy bodies (DLB) |
|
|
633 | (1) |
|
Multisystem atrophy (MSA) |
|
|
633 | (1) |
|
Progressive supranuclear palsy (PSP) |
|
|
633 | (1) |
|
|
633 | (1) |
|
|
633 | (1) |
|
Hyperkinetic movement disorders |
|
|
634 | (1) |
|
|
635 | (1) |
|
Multiple sclerosis and CNS inflammation |
|
|
636 | (5) |
|
|
636 | (4) |
|
Neuromyelitis optica (NMO; `Devic's disease') |
|
|
640 | (1) |
|
Acute disseminated encephalomyelitis (ADEM) and transverse myelitis (TM) |
|
|
640 | (1) |
|
Neurological manifestations of sarcoidosis and Behcet's disease |
|
|
641 | (1) |
|
|
641 | (1) |
|
|
641 | (1) |
|
|
641 | (4) |
|
|
642 | (2) |
|
|
644 | (1) |
|
|
645 | (7) |
|
|
645 | (2) |
|
Disorders of peripheral nerves |
|
|
647 | (1) |
|
Motor neuron disease (MND)/amyotrophic lateral sclerosis |
|
|
647 | (2) |
|
Demyelinating neuropathy and Guillain-Barre syndrome (GBS) |
|
|
649 | (1) |
|
|
650 | (2) |
|
Self-assessment questions |
|
|
652 | (5) |
|
Chapter 19 Psychiatry For The Internist |
|
|
657 | (10) |
|
|
|
|
657 | (1) |
|
|
658 | (1) |
|
|
659 | (1) |
|
Post-traumatic stress disorder (PTSD) |
|
|
659 | (1) |
|
|
659 | (1) |
|
|
660 | (1) |
|
Anorexia and bulimia nervosa |
|
|
661 | (1) |
|
Suicide and deliberate self-harm |
|
|
661 | (1) |
|
|
662 | (3) |
|
|
662 | (1) |
|
|
662 | (1) |
|
|
663 | (1) |
|
|
664 | (1) |
|
Self-assessment questions |
|
|
665 | (2) |
|
Chapter 20 Clinical Infectious Diseases |
|
|
667 | (44) |
|
|
|
Clinical approach to infectious diseases |
|
|
668 | (1) |
|
|
668 | (1) |
|
|
668 | (1) |
|
|
668 | (1) |
|
Diagnostics in infectious diseases |
|
|
669 | (1) |
|
Pre-analytical considerations |
|
|
669 | (1) |
|
Analytical considerations |
|
|
669 | (1) |
|
Post-analytical considerations |
|
|
669 | (1) |
|
Selected common clinically important organisms |
|
|
670 | (7) |
|
|
670 | (2) |
|
|
672 | (2) |
|
|
674 | (3) |
|
|
677 | (1) |
|
|
677 | (3) |
|
|
677 | (1) |
|
What are the likely pathogen(s)? |
|
|
678 | (1) |
|
Are anti-infective drugs required? |
|
|
679 | (1) |
|
Choice of empirical and definitive antibiotics |
|
|
679 | (1) |
|
What host factors need consideration? |
|
|
679 | (1) |
|
What therapy other than antibiotics is required? |
|
|
679 | (1) |
|
Ongoing assessment and further results |
|
|
679 | (1) |
|
What is the duration and endpoint of treatment? |
|
|
679 | (1) |
|
|
680 | (10) |
|
|
680 | (7) |
|
|
687 | (1) |
|
|
688 | (2) |
|
|
690 | (5) |
|
|
690 | (1) |
|
Pyrexia of unknown origin (PUO) |
|
|
690 | (2) |
|
Skin and soft tissue infections |
|
|
692 | (2) |
|
|
694 | (1) |
|
Infections in special hosts and populations |
|
|
695 | (7) |
|
Infections in immunosuppressed patients |
|
|
695 | (1) |
|
Sexually transmitted infections (STIs) |
|
|
696 | (6) |
|
Systemic viral infections |
|
|
702 | (4) |
|
|
702 | (1) |
|
|
702 | (1) |
|
|
702 | (1) |
|
|
703 | (3) |
|
Infection prevention and control |
|
|
706 | (2) |
|
|
706 | (1) |
|
Judicious use of antibiotics |
|
|
707 | (1) |
|
|
707 | (1) |
|
Infection control precautions |
|
|
707 | (1) |
|
|
707 | (1) |
|
|
707 | (1) |
|
Self-assessment questions |
|
|
708 | (3) |
|
|
711 | (16) |
|
|
|
711 | (1) |
|
|
712 | (2) |
|
Factors affecting immunogenicity |
|
|
714 | (1) |
|
Chemical and physical properties of antigens (vaccines) |
|
|
714 | (1) |
|
Physiological attributes of individuals |
|
|
714 | (1) |
|
|
714 | (1) |
|
|
714 | (1) |
|
|
714 | (1) |
|
|
714 | (1) |
|
|
714 | (1) |
|
|
714 | (1) |
|
Immunization in specific populations |
|
|
714 | (5) |
|
|
714 | (1) |
|
|
715 | (1) |
|
|
715 | (1) |
|
|
715 | (4) |
|
|
719 | (1) |
|
Solid-organ transplant patients |
|
|
719 | (1) |
|
Hemopoetic stem-cell transplant (HSCT) recipients |
|
|
719 | (1) |
|
|
719 | (1) |
|
|
719 | (1) |
|
|
719 | (1) |
|
|
719 | (1) |
|
Post-exposure prophylaxis (PEP) |
|
|
719 | (2) |
|
Intramuscular immune globulin |
|
|
719 | (1) |
|
Specific intramuscular immune globulin preparations (hyperimmune globulins) |
|
|
719 | (2) |
|
Specific immune globulins for intravenous use |
|
|
721 | (1) |
|
Routine immunization of adults |
|
|
721 | (1) |
|
Self-assessment questions |
|
|
722 | (5) |
|
Chapter 22 Dermatology For The Physician |
|
|
727 | (12) |
|
|
|
Autoinflammatory diseases of the skin |
|
|
727 | (5) |
|
|
727 | (1) |
|
|
728 | (1) |
|
|
728 | (1) |
|
|
729 | (1) |
|
|
729 | (1) |
|
|
730 | (1) |
|
|
731 | (1) |
|
|
732 | (1) |
|
Skin problems associated with underlying systemic disease |
|
|
732 | (3) |
|
|
732 | (1) |
|
|
733 | (1) |
|
|
734 | (1) |
|
|
734 | (1) |
|
|
734 | (1) |
|
Rash on the palms and soles |
|
|
734 | (1) |
|
Red person syndrome (erythroderma or exfoliative dermatitis) |
|
|
734 | (1) |
|
Excessive sweating (hyperhydrosis) |
|
|
735 | (1) |
|
|
735 | (1) |
|
Genetic or congenital skin diseases |
|
|
735 | (1) |
|
|
735 | (1) |
|
Skin disease associated with malignancy |
|
|
736 | (2) |
|
Primary or secondary malignancy |
|
|
736 | (1) |
|
|
737 | (1) |
|
Self-assessment questions |
|
|
738 | (1) |
|
Chapter 23 Medical Ophthalmology |
|
|
739 | (16) |
|
|
|
|
|
|
739 | (1) |
|
|
740 | (1) |
|
|
740 | (4) |
|
General inspection findings |
|
|
740 | (1) |
|
|
740 | (1) |
|
|
740 | (1) |
|
|
741 | (1) |
|
|
741 | (1) |
|
|
742 | (1) |
|
|
742 | (1) |
|
|
743 | (1) |
|
|
743 | (1) |
|
|
744 | (3) |
|
|
744 | (1) |
|
Retinal arterial occlusion |
|
|
744 | (1) |
|
|
745 | (1) |
|
Diabetic retinopathy (DR) |
|
|
746 | (1) |
|
|
747 | (1) |
|
|
747 | (1) |
|
Thyroid-related orbitopathy |
|
|
747 | (1) |
|
|
748 | (1) |
|
|
748 | (1) |
|
|
749 | (1) |
|
|
749 | (1) |
|
Non-arteritic anterior ischemic optic neuropathy (NAION) |
|
|
749 | (1) |
|
Arteritic anterior ischemic optic neuropathy (AAION) |
|
|
749 | (1) |
|
|
750 | (1) |
|
Extraocular muscle paralysis |
|
|
750 | (1) |
|
|
750 | (1) |
|
Ocular effects of systemic medication |
|
|
750 | (2) |
|
Self-assessment questions |
|
|
752 | (3) |
|
Chapter 24 Women's Health for the Physician |
|
|
755 | (16) |
|
|
|
|
755 | (2) |
|
|
756 | (1) |
|
|
756 | (1) |
|
|
757 | (1) |
|
Infertility due to anatomical abnormalities of the reproductive tract |
|
|
757 | (1) |
|
|
757 | (1) |
|
|
757 | (1) |
|
|
757 | (3) |
|
|
758 | (2) |
|
|
760 | (1) |
|
|
760 | (1) |
|
|
761 | (1) |
|
Abnormal uterine bleeding |
|
|
761 | (1) |
|
|
761 | (1) |
|
|
762 | (1) |
|
|
762 | (1) |
|
|
762 | (3) |
|
|
762 | (1) |
|
Conditions with abnormalities on examination |
|
|
763 | (2) |
|
Sexually transmitted infections (STIs) |
|
|
765 | (1) |
|
|
765 | (1) |
|
|
766 | (1) |
|
Pelvic inflammatory disease (PID) |
|
|
766 | (1) |
|
|
766 | (1) |
|
|
767 | (1) |
|
|
767 | (2) |
|
|
768 | (1) |
|
Self-assessment questions |
|
|
769 | (2) |
|
Chapter 25 Obstetric Medicine |
|
|
771 | (18) |
|
|
|
General principles of medical obstetric care |
|
|
772 | (1) |
|
|
772 | (3) |
|
|
773 | (1) |
|
Type 1 Diabetes in pregnancy |
|
|
774 | (1) |
|
Type 2 Diabetes in pregnancy |
|
|
774 | (1) |
|
Hypertension in pregnancy |
|
|
775 | (2) |
|
|
775 | (1) |
|
Clinical presentation, investigation and diagnosis |
|
|
775 | (1) |
|
|
776 | (1) |
|
Prevention strategies for preeclampsia |
|
|
776 | (1) |
|
Respiratory disease in pregnancy |
|
|
777 | (1) |
|
|
777 | (1) |
|
|
777 | (1) |
|
Venous thromboembolism (VTE) in pregnancy |
|
|
778 | (1) |
|
Thyroid disorders in pregnancy |
|
|
778 | (1) |
|
|
779 | (1) |
|
|
779 | (1) |
|
Common gastroenterological and liver disorders in pregnancy |
|
|
779 | (2) |
|
Gastroesophageal reflux disease (GERD) |
|
|
779 | (1) |
|
Constipation and irritable bowel syndrome (IBS) |
|
|
779 | (1) |
|
Inflammatory bowel disease (IBD) |
|
|
780 | (1) |
|
|
780 | (1) |
|
Acute fatty liver of pregnancy (AFLP) |
|
|
781 | (1) |
|
Budd-Chiari syndrome in pregnancy |
|
|
781 | (1) |
|
Viral infection in pregnancy |
|
|
781 | (1) |
|
|
781 | (1) |
|
Immunological and hematological disease in pregnancy |
|
|
782 | (1) |
|
Systemic lupus erythematosus (SLE) |
|
|
782 | (1) |
|
Antiphospholipid syndrome (APS) |
|
|
782 | (1) |
|
Idiopathic thrombocytopenic purpura (ITP) |
|
|
783 | (1) |
|
Iron-deficiency anemia (IDA) |
|
|
783 | (1) |
|
Cardiac disease in pregnancy |
|
|
783 | (2) |
|
|
783 | (1) |
|
Arrhythmias and palpitations |
|
|
784 | (1) |
|
Cardiomyopathy, including postpartum cardiomyopathy |
|
|
784 | (1) |
|
Other vascular conditions |
|
|
784 | (1) |
|
|
785 | (1) |
|
Neurological conditions in pregnancy |
|
|
785 | (1) |
|
Self-assessment questions |
|
|
786 | (3) |
|
Chapter 26 Geriatric Medicine |
|
|
789 | (18) |
|
|
Balakrishnan Kichu R Nair |
|
|
|
|
|
|
|
790 | (1) |
|
|
790 | (1) |
|
|
790 | (1) |
|
Processes underlying aging |
|
|
790 | (1) |
|
|
790 | (1) |
|
|
790 | (1) |
|
Telomere shortening and mitochondrial dysfunction |
|
|
790 | (1) |
|
Endocrine factors associated with aging |
|
|
790 | (1) |
|
|
791 | (1) |
|
|
791 | (1) |
|
|
791 | (1) |
|
|
791 | (1) |
|
|
791 | (1) |
|
|
791 | (1) |
|
|
791 | (1) |
|
|
791 | (1) |
|
|
792 | (1) |
|
|
792 | (1) |
|
Metabolic and endocrine changes |
|
|
792 | (1) |
|
|
792 | (1) |
|
Pathology: disease in older people |
|
|
792 | (4) |
|
Concepts related to aging |
|
|
792 | (1) |
|
Common problems typical to older people |
|
|
793 | (3) |
|
Atypical presentation of acute illness |
|
|
796 | (1) |
|
|
796 | (1) |
|
Declining mobility and falls |
|
|
796 | (1) |
|
|
796 | (1) |
|
Geriatrics, the 5M's and the role of the Geriatrician |
|
|
797 | (1) |
|
Approach to comprehensive geriatric assessment |
|
|
797 | (1) |
|
|
798 | (1) |
|
|
798 | (1) |
|
|
798 | (1) |
|
|
798 | (1) |
|
|
799 | (1) |
|
|
799 | (1) |
|
|
799 | (1) |
|
|
799 | (1) |
|
|
799 | (1) |
|
|
799 | (1) |
|
|
799 | (1) |
|
Self-assessment questions |
|
|
800 | (7) |
Index |
|
807 | |